American Renal Associates (NYSE:ARA) Upgraded to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of American Renal Associates (NYSE:ARA) from a hold rating to a buy rating in a research note published on Thursday, November 16th. They currently have $13.00 price objective on the stock.

According to Zacks, “American Renal Associates Holdings, Inc. is a provider of dialysis services primarily in the United States. It also offers outpatient and inpatient dialysis treatments for patients suffering from chronic kidney failure. American Renal Associates Holdings, Inc. is based in Beverly, Massachusetts. “

Separately, SunTrust Banks set a $18.00 price objective on American Renal Associates and gave the stock a buy rating in a research note on Sunday, October 15th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. American Renal Associates currently has an average rating of Buy and an average target price of $17.75.

Shares of American Renal Associates (NYSE ARA) traded down $0.40 during trading hours on Thursday, hitting $14.08. The stock had a trading volume of 336,726 shares, compared to its average volume of 150,208. The company has a debt-to-equity ratio of 3.57, a current ratio of 1.16 and a quick ratio of 1.13. The firm has a market capitalization of $455.55, a price-to-earnings ratio of 21.61, a PEG ratio of 1.28 and a beta of 4.29. American Renal Associates has a 12-month low of $9.91 and a 12-month high of $24.82.

American Renal Associates (NYSE:ARA) last issued its quarterly earnings results on Tuesday, November 14th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.16 by $0.03. The firm had revenue of $187.71 million for the quarter, compared to analyst estimates of $194.60 million. American Renal Associates had a positive return on equity of 15.80% and a negative net margin of 2.15%. The business’s revenue was down 2.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.28 earnings per share. analysts forecast that American Renal Associates will post 0.57 earnings per share for the current year.

Several institutional investors have recently made changes to their positions in ARA. Citigroup Inc. lifted its stake in shares of American Renal Associates by 1,876.9% in the 2nd quarter. Citigroup Inc. now owns 8,046 shares of the company’s stock valued at $149,000 after purchasing an additional 7,639 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of American Renal Associates by 19.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 8,778 shares of the company’s stock valued at $162,000 after buying an additional 1,443 shares during the period. Citadel Advisors LLC purchased a new stake in shares of American Renal Associates in the 3rd quarter valued at $200,000. Atria Investments LLC raised its holdings in shares of American Renal Associates by 2.2% in the 2nd quarter. Atria Investments LLC now owns 10,943 shares of the company’s stock valued at $203,000 after buying an additional 233 shares during the period. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of American Renal Associates in the 2nd quarter valued at $230,000. 93.27% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “American Renal Associates (NYSE:ARA) Upgraded to Buy at Zacks Investment Research” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.dispatchtribunal.com/2017/12/04/american-renal-associates-holdings-inc-ara-lifted-to-buy-at-zacks-investment-research.html.

About American Renal Associates

American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.

Get a free copy of the Zacks research report on American Renal Associates (ARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for American Renal Associates Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply